Literature DB >> 14766010

Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.

B M Jaber1, R Mukopadhyay, C L Smith.   

Abstract

The p160 coactivators, steroid receptor coactivator-1 (SRC-1), transcriptional intermediary factor-2 (TIF2) and receptor-associated coactivator-3 (RAC3), as well as the coactivator/integrator CBP, mediate estrogen receptor-alpha (ERalpha)-dependent gene expression. Although these coactivators are widely expressed, ERalpha transcriptional activity is cell-type dependent. In this study, we investigated ERalpha interaction with p160 coactivators and CBP in HeLa and HepG2 cell lines. Basal and estradiol (E2)-dependent interactions between the ERalpha ligand-binding domain (LBD) and SRC-1, TIF2 or RAC3 were observed in HeLa and HepG2 cells. The extents of hormone-dependent interactions were similar and interactions between each of the p160 coactivators and the ERalpha LBD were not enhanced by 4-hydroxytamoxifen in either cell type. In contrast to the situation for p160 coactivators, E2-dependent interaction of the ERalpha LBD with CBP or p300 was detected in HeLa but not HepG2 cells by mammalian two-hybrid and coimmunoprecipitation assays, indicating that the cellular environment modulates ERalpha-CBP/p300 interaction. Furthermore, interactions between CBP and p160 coactivators are much more robust in HeLa than HepG2 cells suggesting that poor CBP-p160 interactions are insufficient to support ERalpha-CBP-p160 ternary complexes important for nuclear receptor-CBP interactions. Alterations in p160 coactivators or CBP expression between these two cell types did not account for differences in ERalpha-p160-CBP interactions. Taken together, these data revealed the influence of cellular environment on ERalpha-CBP/p300 interactions, as well as CBP-p160 coactivator binding, and suggest that these differences may contribute to the cell specificity of ERalpha-dependent gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14766010     DOI: 10.1677/jme.0.0320307

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  7 in total

1.  Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor.

Authors:  Fuzhong F Zheng; Ray-Chang Wu; Carolyn L Smith; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

2.  Genomic-Epidemiologic Evidence That Estrogens Promote Breast Cancer Development.

Authors:  Fritz F Parl; Philip S Crooke; W Dale Plummer; William D Dupont
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

3.  The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities.

Authors:  Kristi L Hoffman; Estrella A Foster; Carolyn L Smith
Journal:  Steroids       Date:  2012-02-02       Impact factor: 2.668

4.  Oncogenic MUC1-C promotes tamoxifen resistance in human breast cancer.

Authors:  Akriti Kharbanda; Hasan Rajabi; Caining Jin; Deepak Raina; Donald Kufe
Journal:  Mol Cancer Res       Date:  2013-03-28       Impact factor: 5.852

5.  Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.

Authors:  Xiang-Rong Jiang; Pan Wang; Carolyn L Smith; Bao Ting Zhu
Journal:  J Med Chem       Date:  2013-03-26       Impact factor: 7.446

6.  Phosphorylation-mediated inactivation of coactivator-associated arginine methyltransferase 1.

Authors:  Ken Higashimoto; Peter Kuhn; Dhaval Desai; Xiaodong Cheng; Wei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-17       Impact factor: 11.205

7.  Effect of estradiol and bisphenol A on human hepatoblastoma cell viability and telomerase activity.

Authors:  B L Xu; Q Z Zhao; X Y Gao; G J Hou
Journal:  Braz J Med Biol Res       Date:  2015-09-18       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.